Dario
DarioHealth Corp. (NASDAQ:DRIO) Dario is changing the way people manage their health, with consumer-friendly digital solutions proven to power lasting behavior change. Dario integrates comprehensive support across a wide range of common and connected health needs, from well-being to chronic condition management, to help our members find long-term success. Billions of data insights from a decade of direct-to-consumer experience fuel Dario’s highly personalized and dynamic member experiences that are constantly adapting to meet changing member needs. This unique approach is proven to keep people engaged in healthier behaviors over time, resulting in high-impact clinical and financial outcomes for our clients. Our mission at Dario is to power the behavior change that drives better health. Investors, please visit: https://dariohealth.investorroom.com/Welcome
Overview
DarioHealth is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue.
Tech Stack
Funding History
Post Ipo Equity
$10.3M
Sep 2018
Post Ipo Equity
$21.3M
Oct 2019
Post Ipo Equity
$28.6M
Jul 2020
Post Ipo Equity
$70.0M
Jan 2021
Farallon Capital Management, Driehaus Capital Management, Nantahala Capital Management +3
Post Ipo Debt
$50.0M
Jun 2022
OrbiMed
Post Ipo Equity
$14.3M
May 2023
Post Ipo Equity
$22.4M
Dec 2023
SternAegis
Post Ipo Equity
$25.6M
Jan 2025
Post Ipo Debt
$32.5M
May 2025
Rand Capital, Callodine Group
Post Ipo Equity
$17.5M
Sep 2025